Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2)

Chia, Audrey; Chua, Wei Ling; Cheung, Yin‐Bun; Wong, Wan Ling; Lingham, Anushia; Fong, Allan; Tan, Donald

doi:10.1016/j.ophtha.2011.07.031

Cited by 603 publications

(804 citation statements)

References 22 publications

Supporting

Mentioning

702

Contrasting

Unclassified

Order By: Relevance

“…Sankaridurg and her colleagues have developed special glasses and contact lenses that can alter eye growth by focusing light from distant images across the entire field of view, rather than just at the centre, as standard lenses do. Other research groups have shown that nightly eye drops with a neurotransmitter-blocking drug called atropine can also help to control myopia progression 14 , although the mechanism remains unclear. "We want to take a holistic approach" to tackling myopia, Sankaridurg says.…”

Section: Time Outmentioning

confidence: 99%

The myopia boom

Dolgin

2015

Nature

743

513

View full text Add to dashboard Cite

Section: Time Outmentioning

confidence: 99%

The myopia boom

Dolgin

2015

Nature

743

513

View full text Add to dashboard Cite

“…12 One study found that the clinical effectiveness of higher concentrations of atropine eye drops is only slightly higher than lower concentration ones in slowing myopia progression among children, although the difference achieved statistical significance. 17 However, treatments with higher concentrations of atropine eye drops are associated with a higher rate of dropout, higher level of photophobia due to larger pupil size, and lower amplitude of accommodation. 12,17 The goal of our study is to investigate the prescription pattern of atropine eye drops among children with myopia in Taiwan from 2000 to 2007.…”

Section: Introductionmentioning

confidence: 99%

“…17 However, treatments with higher concentrations of atropine eye drops are associated with a higher rate of dropout, higher level of photophobia due to larger pupil size, and lower amplitude of accommodation. 12,17 The goal of our study is to investigate the prescription pattern of atropine eye drops among children with myopia in Taiwan from 2000 to 2007. Taiwanese ophthalmologists commonly use atropine as a treatment modality in their daily practice.…”

Section: Introductionmentioning

confidence: 99%

Prescription of atropine eye drops among children diagnosed with myopia in Taiwan from 2000 to 2007: a nationwide study

Yt¹,

Yj²,

Chen³

et al. 2013

Eye

View full text Add to dashboard Cite

Purpose This study was conducted to examine the atropine eye drop prescription trend for children diagnosed with myopia, and to determine the factors associated with the prescription of atropine eye drops. Design This was a population-based cross-sectional study. Methods This study was conducted using a national representative sample from the National Health Insurance (NHI) claims data. All school children between 4 and 18 years of age who had visited an ophthalmologist and were diagnosed with myopia between 2000 and 2007 were included herein. The main outcome measure was the proportion of subjects who were prescribed atropine eye drops in each year. Logistic regression was used to identify the factors associated with atropine eye drops being prescribed. Results The prescription of atropine eye drops for children diagnosed with myopia increased significantly from the school years 2000 (36.9%) to 2007 (49.5%). There was also a shift from prescribing high concentrations (0.5 and 1%) of atropine eye drops to lower concentration ones (0.3, 0.25, and 0.1%) within this period. Atropine eye drops were more frequently prescribed to 9-12-year-old children (OR ¼ 1.26-1.42, compared with those 7-8 years old), and to children from families with a high socioeconomic status (OR ¼ 1.19-1.25); however, they were less prescribed to those living in mid to low urbanized areas . Conclusions This study revealed an increasing trend of atropine eye drop prescription for children with myopia in Taiwan. Our study provides eye-care professionals worldwide a reference for the potential integration of atropine eye drops into their clinical practice toward children with myopia.

show abstract

“…[5][6][7] With that the preliminary results of ongoing studies regarding the efficacy of pirenzepine, increased light exposure (e.g., using the Kurango study lamp) and 7-methylxantine are promising. High-dose atropine was proved to be superior to other interventions.…”

mentioning

confidence: 99%

Treatment of Myopia – Current Status and Recent Advances

Grzybowski¹,

Mazury²

2017

European Ophthalmic Review

View full text Add to dashboard Cite

The incidence of myopia is increasing and represents a major global economic and social burden. In addition to its disadvantages in terms of vision, myopia increases the risk of myopic macular degeneration, retinal detachment, glaucoma and cataract and is a leading cause of visual impairment and blindness worldwide. Pharmacological, environmental and optical interventions have been used to try to slow the progress of myopia. While spectacles and contact lenses have a long history in controlling accommodative responses, they do not slow progression. In an expert interview conducted at EURETINA 2017, Andrzej Grzybowski of the Institute for Research in Ophthalmology, Poznan, Poland discusses the current status of myopia and its treatment, as well as discussing new technologies aimed at delaying progression of the condition.

show abstract

Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2)

Cited by 603 publications

References 22 publications

The myopia boom

The myopia boom

Prescription of atropine eye drops among children diagnosed with myopia in Taiwan from 2000 to 2007: a nationwide study

Treatment of Myopia – Current Status and Recent Advances

Contact Info

Product

Resources

About